Pfizer announced the company’s succession plan for when Ian Read steps down as chief executive officer on January 1, 2019.
Walgreens Boots Alliance Inc. will pay $34.5 million to settle charges that the company misled investors about the increased risk of missing a key financial goal related to its merger in 2012, the top U.S. securities regulator said.
Realm Therapeutics opted to discontinue all drug development programs and is considering a potential sale of the Malvern, Pa.-based company following a clinical trial failure with the atopic dermatitis treatment PR022.
Takeda Pharmaceutical will shutter the company’s Deerfield, Ill., U.S. headquarters and move the operations to Boston as the company consolidates operations following the $62 billion acquisition of Shire. The Illinois facility employs about 1,000 people.
Boston Scientific Corp. forked over up to $160 million to acquire California stent maker Veniti Inc. The deal marks the third acquisition for Boston Scientific in two months.
The Spanish pharmaceutical company Almirall agreed to buy five dermatology brands from U.S. company Allergan for up to $650 million in cash.
Bayer agreed to sell the German drugmaker’s established prescription dermatology brands to Denmark’s Leo Pharma.
The U.S. Justice Department will not challenge the $69 million merger of CVS Health and health insurer Aetna.
Tokyo’s Otsuka Pharmaceutical is acquiring Waltham, Mass.-based Visterra for $430 million in cash. The deal is expected to close during third-quarter 2018.
CURE Pharmaceutical signed a term sheet to acquire the non-pain assets of Therapix Biosciences.